Bio / Bio Monthly: Coinbase Listing, Bio V2, Ignition Sales & BioXP

EcosystemAugust 8, 2025

Bio Monthly: Coinbase Listing, Bio V2, Ignition Sales & BioXP

From Bio V2’s launch and 100M+ BIO staked, to Coinbase listing $BIO and VitaDAO advancing longevity trials. The past month marked key steps in AI-driven science and DeSci adoption.

By Bio Community

Bio Monthly: Coinbase Listing, Bio V2, Ignition Sales & BioXP

Highlights from the past month in the biosphere:

We introduced Bio V2 as a full-stack protocol for accelerating AI-driven science onchain, featuring a new launch and scale model, our new rewards system, BioXP, and staking for both BIO and ecosystem tokens.
We laid out our vision for BioAgents as schelling points for collective scientific intelligence, giving scientists new ways to build community around their research.
BIO was listed on Coinbase alongside ResearchHub (RSC), showing that DeSci is gaining visibility and opening the door for institutions, researchers and builders worldwide to take part.
Within days of BIO and BioDAO staking going live, over 105M BIO (5%+ of circulating supply) has been locked on the protocol.

🧪 Bio V2 Roll-Out

Bio V2 introduces:

Ignition Sales: Bio V2 introduces low-cap, high-velocity raises for new BioAgents, IP-Tokens and BioDAOs.
BioXP: Earn points for staking, ecosystem participation and social engagement. Points determine access to Ignition sales.
Staking BIO & Ecosystem Tokens: Stake BIO and ecosystem tokens (BioAgents, BioDAOs, and IP-Tokens) to earn BioXP.

VitaDAO's VitaRNA project's lead drug candidate ARTAN-102, has taken a significant step toward clinical reality with regulatory discussions in Abu Dhabi. They also shared a VITA-FAST proposal for a potential Phase 2 clinical trial in the UAE. The VitaDAO-supported clinical trial manuscript exploring the effects of Rapamycin and Exercise was submitted for peer review and VitaDAO also hosted a VitaLabs Projects Update event.
Curetopia has consolidated ~40 rare inherited metabolic diseases into a streamlined strategy, successfully completed a pilot for AARS2 and expanded to five additional ARS gene pairs, identifying promising patterns and overlapping rescuers for GARS1 and AARS1, with plans for further research, IP filing, and a proprietary AI data layer in Q3 2025. Learn more in their lab meeting recap.
Long COVID Labs launched a $100,000 Patient Grant Fund to improve treatment access, adopted a faster FDA-compliant strategy. They also introduced a decentralized
Real-World Evidence Platformfor anonymous patient data sharing to prioritize therapies, & awarded a $22,000 grant to a UCSF researcher developing a blood test for SARS-CoV-2 spike protein persistence.
Pump Science released their new platform featuring 17+ new compounds. The next phase of worm experiments for the newly launched compounds has begun.
Cerebrum DAO are allocating 1M BIO from their treasury to develop their NEURON Wallet, enhancing staking, governance, and community engagement. They also hosted their quarterly town hall & a livestream discussing their SK-Channels project, which is developing a small molecule drug to treat ataxia and tremors.
AthenaDAO is testing a saliva-based hormone tracking device for fertility and biomarkers with Ovul in a decentralized clinical trial, while running a pilot study with HealCycle to study how tech can support emotional well-being during the menstrual cycle. They were also featured in a USA Today article for funding innovative ovarian aging research, highlighting their first spinout LifeAhead's algorithm and their F/ACC project, which is advancing ahead of schedule with positive in-vivo data.
HairDAO reported the results of their 6-month observational study showing topical T3 increased hair density, but also noted a slight decrease in hair thickness. They're also entering 13 countries with their first patented product, T3, selling it through their telehealth platform. The DAO also published a new paper on using nanotech to improve hair loss treatments.
Nootropics DAO launched a small-scale Alzheimer's trial and is nearing completion of a large-scale study to factorially assess single- and multi-compound formulations on IQ.
ValleyDAO's Hempy project discovered a new hemp property, softening fibers and making them water-repellent, addressing a key drawback of traditional hemp clothing. Valley also shared Phlo updates including the introduction of ARI, a knowledge graph system for managing project information, and formatting for direct submission to patent offices.
SpineDAO published a peer-reviewed study on PubMED highlighting the need for expert-labeled data in AI models for spinal care. In just days, clinicians labeled 1,875+ patient records with experts earning SPINE based on their contributions.
PsyDAO got funding approved for University of Florida researchon DMT regulation in the brain, targeting inhibitors of DMT biosynthesis for potential therapies in stroke, neurodegeneration, depression and more. They're also partnering up with Pump Science to test the effects of psychedelics on mice. In addition, PsyDAO-backed BeeARD is developing an open-source platform with Coordination Network where agents and multi-agent systems post hypotheses and users can rate and review the hypotheses using replies and reactions.
Molecule introduced MIRA, a domain-literate AI assistant developed with curated, tested sources, demonstrating the potential of high-trust AI to reduce entry barriers in DeSci. They also integrated the Pump.Science tokens on Molecule Labs, to enable users to easily track, trade, and explore all launched compounds.
Quantum Biology DAO is developing a screening platform for magnetosensitivity in bacterial plates, with upcoming additions including imaging, filters for signal isolation, and shielding. They also recently cloned genes into plasmids to study flavoproteins, which are being investigated for their potential sensitivity to magnetic fields.
Spectruth DAO's Ibogaine Wellness Center will soon open to advance PTSD research focusing on active-duty military personnel and veterans. They also put down the deposit on their first mobile diagnostic vehicle, equipped with tech like EEGs and microbiome kits to enable next-gen PTSD care.
D1CK DAO has started beta testing of D1ck AI, a science-based clinical tool designed to address male sexual health issues like priapism